Weon S. Lee
Daejeon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Tie2 activator 4E2 ameliorates diabetic nephropathy and synergizes with dapagliflozin in a mouse model.
Journal: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
Published: December 20, 2024
A ligand-independent Tie2-activating antibody reduces vascular leakage in models of Clarkson disease.
Journal: Science advances
Published: November 17, 2023
An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone.
Journal: Experimental & molecular medicine
Published: July 28, 2022
NMR mapping of the highly flexible regions of 13C/15N-labeled antibody TTAC-0001-Fab.
Journal: Journal of biomolecular NMR
Published: October 30, 2019
Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2.
Journal: Drug design, development and therapy
Published: March 23, 2018
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.
Journal: Investigational new drugs
Published: February 19, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026